The patent protects ActaSim’s design that allows surgeons to use it with ease.
“Receiving the patent is important. It’s also validating seeing the AcatStim-S design so well received by patients and surgeons,” Chris McAuliffe, Theragen’s CEO, said in an Oct. 4 press release. “Our first patent focused on device connectivity, while this patent protects our device design. ActaStim-S offers significant practical advantages versus large, obtrusive devices that can constrain ambulation and mobility.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
